“…Besides serous ovarian tumors, pulmonary, gastrointestinal, endometrial, and breast carcinomas also displayed considerable immunoreactivity for HE4 [11,20]. However, the highest expression was consistently found in epithelial ovarian cancer (EOC) [11,20,21]. Finally, the immunological quantitation of serum HE4 levels was established, and it was rapidly introduced as a novel laboratory marker in EOC [7].…”